Alkermes, INC.
Pharmaceuticals/Health Products
Based in MA
🤖
AI Overview
With $355K in lobbying spend across 9 quarterly filings, Alkermes, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2021 to 2023.
$355K
Total Spend
3
Years Active
1
Firms Hired
4
Lobbyists Deployed
2
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $40K |
| 2022 | $200K |
| 2023 | $115K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Health Issues
- •Access and reimbursement of pharmaceutical products.
- •Access and reimbursement in Medicare Parts B & D. Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
- •Access and reimbursement in Medicare Parts B & D. Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.